Evidence map›Paper›PMID 23415312›Full record

ArticleNeuron2013

Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.

Peter E A Ash, Kevin F Bieniek, Tania F Gendron, Thomas Caulfield, Wen-Lang Lin, Mariely Dejesus-Hernandez, Marka M van Blitterswijk, Karen Jansen-West, Joseph W Paul, Rosa Rademakers and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuron, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 711 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
711citing papers in PubMed, 1 pooled it
70.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

711 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,100 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. RAN Translation-Coupled Decay of theInternational journal of molecular sciences · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

651 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Peter E A AshDepartment of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Kevin F Bieniek
Tania F Gendron
Thomas Caulfield
Wen-Lang Lin
Mariely Dejesus-Hernandez
Marka M van Blitterswijk
Karen Jansen-West
Joseph W Paul
Rosa Rademakers
Kevin B Boylan
Dennis W Dickson
Leonard Petrucelli
Mayo Clinic in Florida · USMayo Clinic in Arizona · US

Funding

Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Charles B Hall · 1985 to 2026
$73.9M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
Stress Granules and the Biology of TDP-43R01ES020395 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WOLOZIN, BENJAMIN L · 2012 to 2016
$4.1M
TDP-43, RNA Metabolism, and ALS/FTD PathologyR01NS063964 · NINDS · UNIVERSITY OF COLORADO · PI LINK, CHRISTOPHER D. · 2009 to 2019
$3.5M
The genetics of chromosome 17q21-linked tau-negative FTDR01AG026251 · NIA · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2006 to 2014
$1.9M
Misregulation of the TDP-43 RNA target, Sortilin, in neurodegenerationR01NS077402 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2011 to 2015
$1.7M
GGGGCC hexanucleotide repeat expansions in neurodegenerative diseaseR01NS080882 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2012 to 2016
$1.6M
Pathologically modified TDP-43 in neurodegenerative diseasesR21NS074121 · NINDS · MAYO CLINIC JACKSONVILLE · PI GENDRON, TANIA FRANCE · 2011 to 2012
$426k
NIA NIH HHS P01 AG003949NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG026251NIEHS NIH HHS R01 ES020395NIEHS NIH HHS R01 ES20395NINDS NIH HHS P50 NS072187NINDS NIH HHS P50 NS72187NINDS NIH HHS R01 NS063964NINDS NIH HHS R01 NS077402NINDS NIH HHS R01 NS080882NINDS NIH HHS R21 NS074121NINDS NIH HHS R21 NS074121-01
6 · The paper itself

Abstract

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are devastating neurodegenerative disorders with clinical, genetic, and neuropathological overlap. Hexanucleotide (GGGGCC) repeat expansions in a noncoding region of C9ORF72 are the major genetic cause of FTD and ALS (c9FTD/ALS). The RNA structure of GGGGCC repeats renders these transcripts susceptible to an unconventional mechanism of translation-repeat-associated non-ATG (RAN) translation. Antibodies generated against putative GGGGCC repeat RAN-translated peptides (anti-C9RANT) detected high molecular weight, insoluble material in brain homogenates, and neuronal inclusions throughout the CNS of c9FTD/ALS cases. C9RANT immunoreactivity was not found in other neurodegenerative diseases, including CAG repeat disorders, or in peripheral tissues of c9FTD/ALS. The specificity of C9RANT for c9FTD/ALS is a potential biomarker for this most common cause of FTD and ALS. These findings have significant implications for treatment strategies directed at RAN-translated peptides and their aggregation and the RNA structures necessary for their production.

Indexed as

Amyotrophic Lateral SclerosisChromosomes, Human, Pair 9DNA Repeat ExpansionFrontotemporal DementiaGene ExpressionGenotypeHumansPeptidesPeptides

Identifiers

PMID23415312
PMCPMC3593233
OpenAlexW1984538960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.